Gilead Sciences Inc Stock
Gilead Sciences Inc Stock
Gilead Sciences Inc gained 1.540% today.
The stock is an absolute favorite of our community with 67 Buy predictions and no Sell predictions.
With a target price of 128 € there is a slightly positive potential of 6.83% for Gilead Sciences Inc compared to the current price of 119.82 €.
So far the community has only identified positive things for Gilead Sciences Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Gilead Sciences Inc in the next few years
Pros
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Gilead Sciences Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | 1.540% | 5.550% | 3.794% | 16.693% | 13.016% | 63.912% | 98.641% |
| Incyte Corp. | -0.720% | 1.703% | 4.084% | 42.409% | 24.080% | 73.530% | 67.845% |
| IQVIA Holdings Inc. | -1.000% | 3.917% | 14.975% | 28.945% | 8.545% | 5.115% | -0.333% |
| Vertex Pharmaceuticals Inc. | -1.560% | 6.604% | 6.149% | 32.334% | 14.360% | 40.160% | 171.979% |
Comments
Gilead Sciences (GILD) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $170.00 price target on the stock.
Show more
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its "overweight" rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Show more
Ratings data for GILD provided by MarketBeat
Gilead Sciences (GILD) had its "overweight" rating reaffirmed by Cantor Fitzgerald.
Show more
Ratings data for GILD provided by MarketBeat